STX140, but not paclitaxel, inhibits mammary tumour initiation and progression in C3(1)/SV40 T/t-antigen transgenic mice.

Article English OPEN
Meyer-Losic, Florence; Newman, Simon P.; Day, Joanna M.; Reed, Michael J.; Kasprzyk, Philip G.; Purohit, Atul; Foster, Paul A.;

Despite paclitxael's clinical success, treating hormone-refractory breast cancer remains challenging. Paclitaxel has a poor pharmacological profile, characterized by a low therapeutic index (TIX) caused by severe dose limiting toxicities, such as neutropenia and periphe... View more
Share - Bookmark